Kodiak Sciences shares rise 6.15% premarket after announcing compelling new data for retinal disease treatments.

Kodiak Sciences Inc. rose 6.15% in premarket trading, with the company announcing recent business highlights and financial results for the second quarter ended June 30, 2025. The company's CEO, Victor Perlroth, M.D., highlighted the transformative potential of their three late-stage clinical assets – tarcocimab, KSI-501, and KSI-101 – in retinal disease treatment. The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to retinal vein occlusion.